Skip to Content
Merck
All Photos(1)

Documents

N1230000

Norfloxacin

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid, 1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-piperazino-3-quinolinecarboxylic acid

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C16H18FN3O3
CAS Number:
70458-96-7
Molecular Weight:
319.33
MDL number:
MFCD00079532
UNSPSC Code:
41116107
PubChem Substance ID:
329818530
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

norfloxacin

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

CCN1C=C(C(O)=O)C(=O)c2cc(F)c(cc12)N3CCNCC3

InChI

1S/C16H18FN3O3/c1-2-19-9-11(16(22)23)15(21)10-7-12(17)14(8-13(10)19)20-5-3-18-4-6-20/h7-9,18H,2-6H2,1H3,(H,22,23)

InChI key

OGJPXUAPXNRGGI-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Norfloxacin EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

Norfloxacin blocks DNA replication by interfering with an ATP-induced structural transition of DNA complexed with DNA gyrase (topoisomerase).
Mode of action: inhibits bacterial DNA replication
Antimicrobial spectrum: Gram-negative bacteria; less effective against Gram-positive bacteria

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

related product

Product No.
Description
Pricing

N1230010

Norfloxacin impurity A, European Pharmacopoeia (EP) Reference Standard

Y0001015

Norfloxacin for system suitability, European Pharmacopoeia (EP) Reference Standard

Y0001301

Norfloxacin for peak identification, European Pharmacopoeia (EP) Reference Standard

1471506

Norfloxacin, United States Pharmacopeia (USP) Reference Standard

1471517

Norfloxacin Related Compound A, United States Pharmacopeia (USP) Reference Standard

1471550

Norfloxacin Related Compound E, United States Pharmacopeia (USP) Reference Standard

1471583

Norfloxacin Related Compound H, United States Pharmacopeia (USP) Reference Standard

1471619

Norfloxacin Related Compound K, United States Pharmacopeia (USP) Reference Standard

BP670

Norfloxacin, British Pharmacopoeia (BP) Reference Standard

PHR2233

Norfloxacin Related Compound A, Pharmaceutical Secondary Standard; Certified Reference Material

Storage Class Code

11 - Combustible Solids

WGK

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Customers Also Viewed

Slide 1 of 1

1 of 1

Trimethoprim ≥98.5%

Sigma-Aldrich

T7883

Trimethoprim

J S Wolfson et al.
Annals of internal medicine, 108(2), 238-251 (1988-02-01)
Norfloxacin is an oral fluoroquinolone antimicrobial agent recently released for the treatment of uncomplicated and complicated urinary tract infections. The drug antagonizes DNA gyrase, an enzyme essential for bacterial DNA replication. Norfloxacin is more potent and broader in spectrum than
Jessica M A Blair et al.
The Journal of antimicrobial chemotherapy, 70(2), 424-431 (2014-10-08)
Enterobacteriaceae have multiple efflux pumps that confer intrinsic resistance to antibiotics. AcrB mediates clinically relevant multidrug resistance and is required for virulence and biofilm formation, making it an attractive target for the design of inhibitors. The aim of this study
Bacterial resistance to norfloxacin and other newer quinolones: pattern and prospects.
D R Nalin
European journal of cancer & clinical oncology, 24 Suppl 1, S55-S61 (1988-01-01)
Ying-Jun Zhou et al.
FEMS microbiology letters, 355(2), 124-130 (2014-05-13)
The antimicrobial activity of one 3-hydroxypyridin-4-one (HPO) hexadentate (1) and three HPO hexadentate-based dendrimeric chelators (2-4) was evaluated. They were found to exhibit marked inhibitory effect on the growth of two Gram-positive bacteria and two Gram-negative bacteria. The combination treatment
L Miano et al.
European urology, 17 Suppl 1, 13-18 (1990-01-01)
A review of worldwide clinical trials with norfloxacin in the treatment of uncomplicated urinary tract infections (UTIs), as well as our personal experience with 215 assessable patients, is presented. Almost all patients received 400 mg b.i.d. for 3-15 days. Bacteriological
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service